S
Sai Life Sciences
Delivers advanced Discovery, Contract Development and Manufacturing Solutions
About Sai Life Sciences
Sai Life Sciences is a global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions to innovator biotech and pharma companies. The company operates in India and internationally, offering services that span the entire drug discovery and development process, from Hit to IND (Investigational New Drug). As a full-service CRO-CDMO, Sai Life Sciences partners with its clients to accelerate their journey in bringing new small molecule drugs to market.
The company's services include chemistry, manufacturing, and controls (CMC), discovery biology, and in-vivo pharmacokinetics (PK) services. With a strong focus on partnership, Sai Life Sciences has established itself as a trusted partner for over 200 companies, delivering a portfolio of molecules at various stages, from discovery to commercial launch. The company has demonstrated consistent growth, positioning itself as one of the fastest-growing CRDMOs among its Indian peers.
In addition to its core business, Sai Life Sciences is committed to sustainability and has joined the Science Based Targets initiative to help combat climate change. This reflects the company's dedication to responsible corporate citizenship alongside its scientific and commercial objectives.
Source: Dealroom company dataAt a glance
- Founded
- 1999
- Headquarters
- India
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sai Life Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sai Life Sciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.




